The ₹75,517 crore market capitalisation company demonstrated strong operational momentum across its specialty chemicals portfolio, with net sales surging 24.31% quarter-on-quarter to ₹4,615.17 crores in Q4 FY26 from ₹3,712.53 crores in Q3 FY26. Year-on-year revenue growth stood at a respectable 7.00% compared to Q4 FY25. The quarter's performance was characterised by margin expansion, improved operational efficiency, and robust demand across key business segments, positioning SRF as a market leader in its operating domains.
However, the stock's post-results reaction suggests that investors are grappling with valuation concerns. Trading at ₹2,527.60, SRF has underperformed significantly over the past year, delivering negative returns of 15.38% compared to the Sensex's decline of 4.68%, resulting in a concerning alpha of -10.70%. The stock currently trades 23.84% below its 52-week high of ₹3,319.00, whilst remaining just 9.24% above its 52-week low of ₹2,313.75, reflecting sustained selling pressure despite improving fundamentals.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin |
|---|---|---|---|---|---|
| Mar'26 | 4,615.17 | +24.31% | 582.02 | +34.52% | 22.63% |
| Dec'25 | 3,712.53 | +1.99% | 432.66 | +11.46% | 21.60% |
| Sep'25 | 3,640.19 | -4.67% | 388.18 | -10.21% | 21.90% |
| Jun'25 | 3,818.62 | -11.47% | 432.32 | -17.82% | 22.20% |
| Mar'25 | 4,313.34 | +23.55% | 526.06 | +94.06% | 22.71% |
| Dec'24 | 3,491.31 | +1.96% | 271.08 | +34.58% | 18.19% |
| Sep'24 | 3,424.30 | — | 201.42 | — | 16.14% |
Financial Performance: Margin Expansion Drives Profitability
SRF's Q4 FY26 financial performance showcased impressive margin improvement alongside robust top-line growth. Operating profit (PBDIT excluding other income) surged to ₹1,025.68 crores in Q4 FY26, representing the highest quarterly operating profit in the company's recent history. This translated to an operating margin of 22.63%, marking a sequential improvement of 103 basis points from 21.60% in Q3 FY26 and essentially matching the 22.71% achieved in Q4 FY25.
The margin expansion was driven by improved operational efficiency and better cost management. Employee costs rose moderately to ₹313.10 crores in Q4 FY26 from ₹280.84 crores in Q3 FY26, reflecting controlled personnel expenses despite business growth. Interest costs declined sequentially to ₹61.96 crores from ₹65.50 crores, demonstrating improving financial leverage. Depreciation increased marginally to ₹219.81 crores from ₹216.89 crores, in line with ongoing capital investments.
Profit before tax reached ₹757.10 crores in Q4 FY26, surging 67.63% quarter-on-quarter from ₹451.67 crores in Q3 FY26 and improving 7.03% year-on-year from ₹707.36 crores in Q4 FY25. The effective tax rate stood at 23.13% in Q4 FY26, significantly higher than the unusually low 4.21% in Q3 FY26 but lower than the 25.63% in Q4 FY25, reflecting normalised tax provisions. PAT margin expanded to 12.84% in Q4 FY26 from 11.98% in Q3 FY26, demonstrating improved bottom-line efficiency.
Operational Excellence: Market Leadership With Strong Returns
SRF's operational metrics underscore its position as a quality specialty chemicals manufacturer with strong competitive advantages. The company's average return on equity (ROE) of 16.23% over recent years demonstrates efficient capital deployment and healthy profitability. This ROE performance, whilst lower than the latest quarterly ROE of 12.20%, reflects the company's ability to generate attractive returns on shareholder capital in a capital-intensive industry.
Return on capital employed (ROCE) averaged 17.20% over the assessment period, indicating superior returns on total capital deployed in the business. The latest ROCE of 13.79% suggests some moderation but remains respectable for the sector. The company's EBIT to interest coverage ratio averaged an impressive 11.99 times, demonstrating robust debt servicing capability and financial stability. In Q4 FY26 specifically, operating profit to interest coverage reached a remarkable 16.55 times, the highest in recent quarters.
Balance sheet quality remains a key strength, with average debt to EBITDA ratio of 1.54 times indicating low leverage. Net debt to equity averaged just 0.30 times, reflecting conservative financial management. Long-term debt stood at ₹1,981.33 crores as of March 2025, down from ₹2,251.14 crores in March 2024, demonstrating deleveraging efforts. Shareholder funds increased to ₹12,626.20 crores from ₹11,479.02 crores, driven by retained earnings and operational cash generation.
Key Operational Strengths
Market Leadership: SRF holds the #2 position in the specialty chemicals sector with operations across India, Thailand, South Africa, and Hungary. The company's diversified geographic footprint and dominant market positions in most business segments provide competitive advantages and pricing power.
Strong Cash Generation: Operating cash flow of ₹2,487 crores in FY25 demonstrates robust cash generation capability, supporting capital investments of ₹1,482 crores whilst maintaining healthy free cash flow.
Margin Dynamics: Sustained Improvement Trajectory
The margin profile improvement in Q4 FY26 represents a continuation of the positive trend observed over recent quarters. Operating margin (excluding other income) has expanded from 16.14% in September 2024 to 22.63% in March 2026, representing a substantial 649 basis points expansion over six quarters. This improvement reflects successful cost optimisation initiatives, favourable product mix shifts, and operational leverage benefits from volume growth.
Gross profit margin reached 21.56% in Q4 FY26, up from 18.51% in Q3 FY26, indicating improved pricing power and better raw material cost management. The company's ability to maintain margins above 20% despite a challenging operating environment demonstrates the resilience of its business model and the quality of its product portfolio. PAT margin of 12.84% in Q4 FY26 compares favourably to the historical average and reflects improving profitability across the value chain.
Other income moderated to ₹24.90 crores in Q4 FY26 from ₹27.33 crores in Q3 FY26 and ₹34.49 crores in Q4 FY25, indicating reduced reliance on non-operating income. The company's core operating performance has strengthened sufficiently to drive overall profitability without depending on treasury income or one-time gains.
| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Operating Margin | 22.63% | 21.60% | 22.71% | +103 bps | -8 bps |
| Gross Margin | 21.56% | 18.51% | 21.41% | +305 bps | +15 bps |
| PAT Margin | 12.84% | 11.98% | 12.48% | +86 bps | +36 bps |
| Interest Coverage | 16.55x | 11.91x | 10.71x | +4.64x | +5.84x |
Industry Leadership: How SRF Compares to Peers
Within the specialty chemicals sector, SRF occupies a unique position with its scale, diversification, and operational track record. Compared to sector peers, the company demonstrates competitive advantages in certain metrics whilst facing valuation challenges in others. With a market capitalisation of ₹75,517 crores, SRF ranks as the second-largest company in the specialty chemicals sector, trailing only the significantly larger Pidilite Industries.
From a profitability perspective, SRF's ROE of 16.23% positions it favourably against peers such as Gujarat Fluorochemicals (10.77%), Navin Fluorine International (13.77%), and Himadri Speciality Chemical (11.70%), though it lags Pidilite Industries (21.78%) and Deepak Nitrite (21.28%). This ROE performance reflects SRF's efficient capital deployment and strong competitive positioning across its business segments.
On valuation metrics, SRF trades at a price-to-earnings ratio of 40.78 times, which is lower than Pidilite Industries (59.97x), Gujarat Fluorochemicals (61.49x), and Navin Fluorine International (53.57x), but higher than Deepak Nitrite (44.51x) and Himadri Speciality Chemical (41.30x). The company's price-to-book ratio of 5.69 times is moderate compared to Pidilite's premium 14.53 times but higher than Deepak Nitrite's 4.38 times, reflecting investor recognition of SRF's quality and growth prospects tempered by recent performance concerns.
| Company | P/E Ratio | P/BV Ratio | ROE % | Div Yield % | Debt/Equity |
|---|---|---|---|---|---|
| SRF | 40.78 | 5.69 | 16.23 | 0.35 | 0.30 |
| Pidilite Industries | 59.97 | 14.53 | 21.78 | 1.10 | -0.29 |
| Gujarat Fluorochemicals | 61.49 | 5.39 | 10.77 | 0.08 | 0.20 |
| Navin Fluorine Intl. | 53.57 | 9.02 | 13.77 | 0.19 | -0.01 |
| Himadri Speciality | 41.30 | 6.59 | 11.70 | 0.10 | -0.02 |
| Deepak Nitrite | 44.51 | 4.38 | 21.28 | 0.42 | 0.17 |
SRF's dividend yield of 0.35% remains modest compared to peers, reflecting the company's preference for reinvesting profits into growth initiatives rather than distributing high dividends. The latest dividend of ₹5 per share with a payout ratio of 17.12% indicates conservative dividend policy focused on capital retention for expansion. This approach aligns with the company's ongoing capital expenditure programme and strategic investments in capacity expansion.
Valuation Analysis: Premium Pricing Despite Recent Weakness
At the current market price of ₹2,527.60, SRF trades at demanding valuation multiples that reflect both its quality credentials and market leadership position, whilst also incorporating concerns about near-term growth prospects. The trailing twelve-month P/E ratio of 40.78 times represents a significant premium to the broader market but a discount to several specialty chemicals peers. This valuation is categorised as "Very Expensive" based on historical context and peer comparison.
The price-to-book ratio of 5.69 times indicates that investors are willing to pay a substantial premium over book value, recognising the company's intangible assets, market position, and earnings power. However, this multiple has compressed from higher levels observed during the stock's peak, reflecting the 23.84% decline from the 52-week high of ₹3,319.00. The EV/EBITDA multiple of 23.76 times and EV/EBIT of 31.58 times further underscore the premium valuation.
The PEG ratio of 0.67 suggests that the stock may offer reasonable value when growth prospects are factored in, as a PEG below 1.0 typically indicates potential undervaluation relative to growth. With five-year sales growth of 15.15% and EBIT growth of 11.99%, the company has demonstrated consistent expansion, though recent quarters have shown some moderation in growth momentum.
Shareholding: Institutional Confidence Building Gradually
The shareholding pattern reveals interesting dynamics in institutional investor behaviour towards SRF. Promoter holding has remained rock-solid at 50.26% over the past five quarters, with Kama Holdings Limited holding 50.21% and the Bharat Ram family members holding marginal stakes. The absence of any promoter pledging demonstrates strong financial health and confidence in the company's prospects.
Foreign institutional investor (FII) holding has witnessed a gradual decline from 18.27% in March 2025 to 16.66% in March 2026, representing a cumulative reduction of 161 basis points over four quarters. This selling pressure from FIIs, particularly the 82 basis points decline in Q4 FY26 alone, has contributed to the stock's underperformance. The reduction suggests that global investors may be taking profits or reallocating capital to other opportunities.
In contrast, mutual fund holdings have shown a consistent upward trajectory, increasing from 9.06% in March 2025 to 12.33% in March 2026, marking an addition of 327 basis points. The sequential quarterly increases of 130 basis points, 65 basis points, 66 basis points, and 66 basis points demonstrate steady accumulation by domestic institutional investors. This divergence between FII selling and mutual fund buying indicates differing views on the stock's prospects.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 50.26% | 50.26% | 50.26% | 50.26% | 0.00% |
| FII Holding | 16.66% | 17.48% | 17.98% | 18.23% | -0.82% |
| Mutual Fund | 12.33% | 11.67% | 11.01% | 10.36% | +0.66% |
| Insurance | 7.00% | 6.89% | 7.37% | 7.47% | +0.11% |
| Other DII | 1.88% | 1.66% | 1.19% | 1.06% | +0.22% |
Insurance company holdings have remained relatively stable at 7.00% in March 2026, down from 7.95% in March 2025, showing modest reduction. Other domestic institutional investor (DII) holdings increased to 1.88% from 1.46%, indicating growing interest from pension funds and other institutional players. Overall institutional holding stands at 37.87%, providing a stable shareholder base and reducing volatility.
Stock Performance: Persistent Underperformance Raises Concerns
SRF's stock price performance over the past year has been disappointing, with the shares declining 15.38% compared to the Sensex's fall of 4.68%, resulting in negative alpha of 10.70%. This underperformance is particularly concerning given the company's improving operational metrics and strong Q4 FY26 results. The stock's weakness extends across multiple timeframes, with year-to-date returns of -17.79% significantly lagging the Sensex's decline of 9.63%.
The three-month and six-month returns paint a similar picture, with the stock falling 13.00% and 14.04% respectively, compared to Sensex declines of 7.56% and 7.72%. This consistent underperformance across different time horizons suggests structural concerns beyond short-term volatility. Investors appear to be questioning whether the current valuation adequately reflects the growth prospects and potential headwinds facing the specialty chemicals sector.
However, taking a longer-term perspective reveals a different narrative. Over five years, SRF has delivered impressive returns of 84.73% compared to the Sensex's 58.22%, generating positive alpha of 26.51%. The ten-year performance is even more remarkable, with returns of 814.74% vastly outpacing the Sensex's 204.87%, demonstrating the wealth-creation potential of quality chemical companies over extended periods.
| Period | SRF Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -0.21% | 0.17% | -0.38% |
| 1 Month | 4.65% | 5.04% | -0.39% |
| 3 Months | -13.00% | -7.56% | -5.44% |
| 6 Months | -14.04% | -7.72% | -6.32% |
| YTD | -17.79% | -9.63% | -8.16% |
| 1 Year | -15.38% | -4.68% | -10.70% |
| 2 Years | -1.51% | 4.25% | -5.76% |
| 3 Years | -0.06% | 26.15% | -26.21% |
| 5 Years | 84.73% | 58.22% | +26.51% |
| 10 Years | 814.74% | 204.87% | +609.87% |
From a technical perspective, SRF currently exhibits a "Mildly Bearish" trend that changed on May 4, 2026. The stock trades below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating sustained selling pressure. Immediate support lies at the 52-week low of ₹2,313.75, whilst resistance emerges at the 20-day moving average of ₹2,485.43, followed by the 100-day moving average at ₹2,738.33.
Investment Thesis: Quality Company At Crossroads
SRF presents a complex investment proposition that balances strong operational fundamentals against valuation concerns and deteriorating technical momentum. The company's Mojo Score of 48 out of 100 translates to a "SELL" rating, reflecting the challenging near-term outlook despite long-term quality credentials. This rating considers four key dimensions: valuation (Very Expensive), quality (Good), financial trend (Positive), and technical trend (Mildly Bearish).
The quality assessment of "Good" recognises SRF's strong competitive position, healthy balance sheet, consistent cash generation, and market leadership. The company's five-year sales CAGR of 15.15%, average ROE of 16.23%, and average ROCE of 17.20% demonstrate sustained value creation. Zero promoter pledging and institutional holdings of 37.87% further validate the quality thesis.
However, the "Very Expensive" valuation grade highlights the premium pricing that leaves little room for disappointment. The P/E ratio of 40.78 times, whilst lower than some peers, remains elevated in absolute terms. The recent shift in the Mojo Score from "HOLD" (64 points) on October 27, 2025, to "SELL" (48 points) currently reflects deteriorating technical conditions and valuation concerns outweighing fundamental improvements.
Mojo 4 Dots Assessment
Near-Term Drivers: MIXED – Positive quarterly financial trend offset by mildly bearish technical indicators
Quality: GOOD – Strong fundamentals, market leadership, healthy balance sheet
Valuation: VERY EXPENSIVE – Trading at premium multiples with limited margin of safety
Overall: MIXED – Conflicting signals across parameters warrant caution
Key Strengths & Risk Factors
KEY STRENGTHS
- Market Leadership: Second-largest specialty chemicals company with dominant positions across business segments and global operations in four countries
- Strong Profitability: Consistent ROE of 16.23% and ROCE of 17.20% demonstrate efficient capital deployment and competitive advantages
- Robust Cash Generation: Operating cash flow of ₹2,487 crores in FY25 supports growth investments whilst maintaining financial flexibility
- Healthy Balance Sheet: Low net debt-to-equity of 0.30 times and debt-to-EBITDA of 1.54 times provide financial stability
- Margin Expansion: Operating margin improved from 16.14% to 22.63% over six quarters, demonstrating operational leverage
- Zero Promoter Pledging: Reflects strong promoter confidence and financial health
- Growing Domestic Institutional Support: Mutual fund holding increased from 9.06% to 12.33% over past year
KEY CONCERNS
- Expensive Valuation: P/E of 40.78x and P/BV of 5.69x leave limited margin of safety and high expectations for growth
- Persistent Underperformance: Stock down 15.38% over past year versus Sensex decline of 4.68%, generating negative alpha of 10.70%
- FII Selling Pressure: Foreign institutional holding declined from 18.27% to 16.66% over past year, indicating reduced global investor interest
- Bearish Technical Trend: Stock trading below all major moving averages with mildly bearish technical indicators
- Cyclical Industry: Specialty chemicals sector subject to demand volatility, raw material price fluctuations, and global economic cycles
- Low Dividend Yield: 0.35% yield provides minimal income support during price weakness
- Distance from Peak: Stock trading 23.84% below 52-week high of ₹3,319, indicating sustained selling pressure
Outlook: What to Watch
POSITIVE CATALYSTS
- Sustained margin expansion above 22% levels demonstrating pricing power and cost control
- Revenue growth acceleration beyond current 7% YoY pace indicating demand recovery
- Further mutual fund accumulation supporting stock price stabilisation
- Capacity utilisation improvements driving operating leverage benefits
- New product launches or capacity additions enhancing growth prospects
RED FLAGS
- Continued FII selling pressure accelerating beyond recent pace
- Margin compression from raw material cost inflation or competitive pressures
- Revenue growth deceleration or sequential decline in coming quarters
- Break below 52-week low of ₹2,313.75 signalling technical breakdown
- Global economic slowdown impacting specialty chemicals demand
Looking ahead, SRF's trajectory will depend on its ability to sustain the margin expansion demonstrated in Q4 FY26 whilst accelerating revenue growth. The company's strong operational fundamentals and market leadership position it well for long-term value creation, but near-term headwinds from valuation concerns and technical weakness warrant a cautious approach. Investors should monitor quarterly results for evidence of sustained momentum and watch for technical trend reversal signals before considering fresh positions.
The divergence between improving fundamentals and deteriorating stock price creates a challenging environment for investment decisions. Whilst long-term investors with existing positions may choose to hold given the quality credentials, fresh investors face limited margin of safety at current valuations. The stock's classification as "Medium Risk Low Return" based on one-year risk-adjusted metrics further supports a cautious stance.
The Verdict: Quality Company Facing Valuation Headwinds
Score: 48/100
For Fresh Investors: Avoid initiating positions at current levels. The combination of expensive valuation (P/E 40.78x), bearish technical trend, and persistent underperformance suggests limited upside potential in the near term. Wait for either a significant price correction towards ₹2,200-2,300 levels or clear technical trend reversal before considering entry.
For Existing Holders: Consider reducing positions on any rally towards ₹2,650-2,700 levels to book partial profits. Whilst the company's long-term fundamentals remain intact, the current risk-reward ratio is unfavourable. Maintain core holdings only if conviction in long-term prospects remains strong and portfolio allocation is not excessive.
Fair Value Estimate: ₹2,100-2,200 (17% downside from current levels), based on normalised P/E of 32-35x applied to trailing earnings, reflecting quality premium but accounting for valuation compression risk.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
